# Semnur Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/semnur-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Los Altos, US
- Website: www.semnurpharmaceuticals.com
- Total disclosed funding: $16M
- Latest round: Series A (Jan 9, 2015)
- Investors on record: 3

## About

Semnur Pharmaceuticals, Inc. is dedicated to developing and commercializing innovative non-opioid therapeutics for chronic pain management, particularly targeting conditions like lumbar radicular pain and sciatica.Founded in 2013 in Los Altos, US, Semnur Pharmaceuticals, Inc. focuses on creating non-opioid solutions for chronic pain. The company was acquired by Scintilla Pharmaceuticals, Inc. in August 2016 for an initial USD 60 mn, with additional performance-based payments. The CEO, Jaisim S, leads the organization.Semnur Pharmaceuticals, Inc. specializes in the development and commercialization of novel non-opioid therapeutics aimed at addressing chronic pain management, focusing on conditions such as lumbar radicular pain (sciatica). Their flagship product, SP-102 (SEMDEXA™), is a preservative-free injectable corticosteroid gel formulation designed for moderate to severe chronic radicular pain, providing pain relief through targeted transforaminal injections. Created for the U.S. market, SP-102's efficacy was demonstrated in the Phase 3 C.L.E.A.R. Clinical Research Study involving a large patient population across multiple U.S. sites.Operating through a B2B model, Semnur Pharmaceuticals generates revenue by collaborating with healthcare practitioners and pain management specialists, selling SP-102 (SEMDEXA™) to healthcare facilities like hospitals and pain management clinics. This proprietary product is used in epidural steroid injection procedures for sciatica patients. While specific pricing details have not been disclosed, anticipated revenue will stem from these product sales, targeting a significant market share in chronic pain management.Following the acquisition in August 2016, Semnur Pharmaceuticals plans to utilize the recent funding to support the expansion of SP-102 (SEMDEXA™) and may introduce new products to address chronic pain management. The company aims to broaden its market reach, particularly in new geographic regions, though specific plans and timelines have not been detailed.

## Funding rounds

- Series A, Jan 9, 2015, $10M — Frazier Healthcare Partners, Canaan Partners, Vivo Capital
- Series A, Aug 6, 2013, $6M — Frazier Healthcare Partners, Canaan Partners, Vivo Capital

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A